Jason Gotlib

Jason Gotlib led the pivotal clinical trials of avapritinib for systemic mastocytosis driven by the KIT D816V mutation, achieving unprecedented response rates in a disease previously lacking targeted therapy and establishing avapritinib as a breakthrough treatment for advanced mastocytosis. His PATHFINDER and PIONEER trials demonstrated deep molecular responses with reduction of the KIT D816V allele burden. He has been instrumental in defining response criteria for mastocytosis clinical trials. His clinical research has transformed the treatment landscape for mast cell neoplasms.